It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
The approval introduces a needle-free alternative to injectable GLP-1 therapies
The accelerated review covers WCK 5222 for multiple critical infections
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
Full approval will depend on verification of clinical benefit in a confirmatory trial
NUFYMCO BLA has been approved by the USFDA
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
Subscribe To Our Newsletter & Stay Updated
